Published in Managed Care Law Weekly, August 26th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at GlaxoSmithKline.
Report 1: GlaxoSmithKline announced positive data from three key studies on its first-in-class, oral small molecule HER2 kinase inhibitor, TYKERB(R) (lapatinib). Results of these and other important TYKERB studies are being presented this week at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois. The use of TYKERB in these settings is investigational.
"The robust clinical data presented for TYKERB at ASCO further...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly